Sign in
Not yet taking people in United StatesPhase 4

Zynrelef compared with a nerve block for pain after knee replacement for knee osteoarthritis

Compares Zynrelef with a nerve block for opioid use after knee replacement surgery.

Key facts

Who runs it
University of Miami
Where
Miami, United StatesSee the site
Trial code
Registry title
Zynrelef Versus Adductor Canal Block
Status
Not yet recruiting
Phase
Phase 4
People taking part
120 people, planned
Starts
Jan 2027
Expected to end
Jan 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ZYNRELEF 400Mg-12Mg Extended-Release Solution
  • Ultrasound-Guided Adductor Canal Block
  • Ropivacaine 0.5% Injectable Solution
Record updated
12 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having a first-time total knee replacement on one knee. It compares Zynrelef placed in the knee during surgery with an adductor canal block (a nerve numbing injection) for pain after surgery.

Age
Over 18 years.
Sex
All sexes.
Disease stage
People having a primary (first-time), one-sided total knee replacement. American Society of Anesthesiologists Physical Status score of 3 or lower.
Earlier treatment
No long-acting opioids within 3 days, no opioids within 24 hours, and no Bupivacaine HCL within 5 days before surgery. No daily opioid use for seven or more days in a row within 6 months before surgery.

Main reasons for not taking part

  • Pregnant women, prisoners, and adults unable to give consent cannot join.
  • Illegal drug use, or alcohol abuse with a CAGE score of two or more.
  • Known serious allergy to amide-type local anesthetics, NSAIDs, or any part of ZYNRELEF.
  • History of asthma, hives or other allergic reactions after aspirin or other NSAIDs.
  • Chronic opioid use.

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients > 18 years of age
  • Patients undergoing primary, unilateral total knee arthroplasty
  • Ability to provide informed consent

Who cannot take part

  • Patients taking any of the following medications before surgery:
  • Chronic opioid use or patients with known or suspected daily use of opioids for seven or more consecutive days within 6 months before their scheduled surgery
  • Illicit drug use determined by social history
  • Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF
  • Patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients
  • Individuals under the age of 18
  • Pregnant women
  • Prisoners
  • Adults unable to consent
  • American Society of Anesthesiologists Physical Status score greater than 3
  • Long-acting opioids within 3 days
  • Any opioids taken within 24 hours
  • Bupivacaine HCL within 5 days
  • Alcohol abuse determined by a CAGE Substance Abuse Screening Tool Score of at least two or greater

Where in United States

  • University of MiamiMiami, United StatesContact: Natalia Cruz, MDNot yet recruiting

About the trial

What the trial wants to find out

To compare postoperative MME consumption 72 hours after TKA in patients receiving intraoperative periarticular HTX-011 (Zynrelef) instillation versus adductor canal block.

The 2 groups in the trial

  • Zynrelef (HTX-011) with application procedureTreatment being tested

    Participants in this group will receive intraoperative analgesia via application of ZYNRELEF (HTX-011) directly into the periarticular tissues at the surgical site following prosthesis implantation and prior to capsule closure. The medication will be applied by the surgeon using sterile technique per manufacturer instructions, targeting the posterior capsule, medial and lateral gutters, and surrounding soft tissues.

    Treatment: ZYNRELEF 400Mg-12Mg Extended-Release Solution

  • Adductor canal block (ACB)Existing treatment, for comparison

    Participants in this group will receive a postoperative ultrasound-guided adductor canal block performed by a board-certified anesthesiologist or regional anesthesia-trained provider. The procedure will be conducted under sterile conditions while the patient remains under spinal anesthesia.

    Treatment: Ultrasound-Guided Adductor Canal Block and Ropivacaine 0.5% Injectable Solution

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparing Opioid Consumption Following Total Knee Arthroplasty With The Perioperative Administration of Zynrelef Versus Adductor Canal Block
Plain-language title
Zynrelef compared with a nerve block for pain after knee replacement for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
12 June 2026